The great divide: Why royalty financing conquered North America but struggles everywhere else
Royalty financing in biotech and healthcare has exploded into a $5-6 billion annual market in North America, with transactions growing
Fund of the Week: Blackstone Life Sciences
Background and Evolution
Blackstone Life Sciences (BXLS) is the life-sciences investment arm of Blackstone, the world's largest alternative
Company of the week Soufflé Therapeutics
A delicate French dessert must rise perfectly under precise conditions. In biotechnology, Soufflé Therapeutics — a newly unveiled venture named after
Variable Capital Companies (VCCs) in Singapore's Healthcare and Life Sciences Investments
Introduction
The Variable Capital Company (VCC) represents a transformative development in Singapore's fund management landscape, particularly for healthcare
Special Purpose Vehicles in Pharma & Biotech – An In-Depth Explainer
Introduction
Special Purpose Vehicles (SPVs) play a pivotal role in the pharmaceutical and biotechnology sectors, facilitating innovative financing and structuring
Understanding Bankruptcy Remoteness in Biotech Royalty Financing Deals
Bankruptcy remoteness is a crucial concept in structuring financial deals — especially royalty financing transactions in the biotechnology and pharmaceutical industry.
The Weekly Term Sheet (41)
The week saw concentrated M&A activity focused on MASH and neurological assets totalling over $10 billion in deal
Milestones and Mirages: Biotech's Big-Deal Delusions
The Allure of the "Up To" Deal
Every so often, a biotech startup announces a blockbuster partnership with
Fund of the week: CureDuchenne Ventures
Executive Summary
CureDuchenne Ventures does not operate as a traditional venture capital firm. Instead, it represents a venture philanthropy model
Company of the week: Rome Therapeutics
Introduction
Rome Therapeutics is a Boston-based biotechnology company on a mission to drug the "dark genome" – the vast
